Abbott joins alliance to bring 'artificial pancreas' system to Europe | ABT Message Board Posts


Abbott Laboratories

  ABT website

ABT   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  78 of 86  at  4/30/2022 12:55:01 PM  by

jerrykrause


Abbott joins alliance to bring 'artificial pancreas' system to Europe

 Pharma & Healthcare Monitor Worldwide
 
 

Abbott joins alliance to bring 'artificial pancreas' system to Europe

 
 

The three-way partnership brings Abbotts FreeStyle Libre 3 wearable sensor with a mobile app developed by Camdiab that communicates with an insulin pump developed by Ypsomed.

When used together, the three technologies form an artificial pancreas, responding to fluctuating blood glucose levels with delivery of an appropriate dose of insulin in real-time.

The three companies say the combined use of the three technologies will help lessen the burden of disease management for people with diabetes, and remove the guesswork from insulin dosing using conventional means.

Poor glucose control leads to an increased risk of diabetes complications such as blindness, and heart and kidney disease, said Roman Hovorka, director of CamDiab, whose artificial intelligence-powered CamAPS FX app is already approved for use in the EU and UK for use in type 1 diabetes patients down to one year of age.

Once development of the AID is completed expected by the end of the year it will lift the burden of managing a condition that is relentlessly unpredictable day and night, he added.

CamDiab and Ypsomed have been working together on a smartphone-based AID since March, bundling the CamAPS FX app with Ypsomeds mylife YpsoPump in an offering that has already started to roll out in some European countries.

Adding Abbott to the alliance closes the circle, moving close to an entirely automated system for people with diabetes.

Abbotts wearable continuous glucose monitor (CGM) is billed as the smallest and thinnest real-time system available, and last month became available via the NHS to eligible type 1 diabetes patients across the UK, as well as some insulin-dependent type 2 patients.

The system consists of a sensor, around the size of a 1 coin, that is worn on the upper arm and an app, which can be used by users to record their real-time glucose levels, history and trends.

 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 0  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...